Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Recent data indicate the presence of liver enzyme abnormalities in patients with coronavirus disease 2019 (COVID-19). We aimed to evaluate the clinical features and treatment outcomes of COVID-19 patients with abnormal liver enzymes. Methods: We performed a retrospective, multicenter study of 874 COVID-19 patients admitted to five tertiary hospitals from February 20 to April 14, 2020. Data on clinical features, laboratory parameters, medications, and treatment outcomes were collected until April 30, 2020, and compared between patients with normal and abnormal aminotransferases. Results: Abnormal aminotransferase levels were observed in 362 patients (41.1%), of which 94 out of 130 (72.3%) and 268 out of 744 (36.0%) belonged to the severe and non-severe COVID- 19 categories, respectively. The odds ratios (95% confidence interval) for male patients, patients with a higher body mass index, patients with severe COVID-19 status, and patients with lower platelet counts were 1.500 (1.029 to 2.184, p=0.035), 1.097 (1.012 to 1.189, p=0.024), 2.377 (1.458 to 3.875, p=0.001), and 0.995 (0.993 to 0.998, p>0.001), respectively, indicating an independent association of these variables with elevated aminotransferase levels. Lopinavir/ ritonavir and antibiotic use increased the odds ratio of abnormal aminotransferase levels after admission (1.832 and 2.646, respectively, both p<0.05). The median time to release from quarantine was longer (22 days vs 26 days, p=0.001) and the mortality rate was higher (13.0% vs 2.9%, p<0.001) in patients with abnormal aminotransferase levels. Conclusions: Abnormal aminotransferase levels are common in COVID-19 patients and are associated with poor clinical outcomes. Multivariate analysis of patients with normal aminotransferase levels on admission showed that the use of lopinavir/ritonavir and antibiotics was associated with abnormal aminotransferase levels; thus, careful monitoring is needed.
Abstract
Background/Aims: Recent data indicate the presence of liver enzyme abnormalities in patients with coronavirus disease 2019 (COVID-19). We aimed to evaluate the clinical features and treatment outcomes of COVID-19 patients with abnormal liver enzymes. Methods: We performed a retrospective, multicenter study of 874 COVID-19 patients admitted to five tertiary hospitals from February 20 to April 14, 2020. Data on clinical features, laboratory parameters, medications, and treatment outcomes were collected until April 30, 2020, and compared between patients with normal and abnormal aminotransferases. Results: Abnormal aminotransferase levels were observed in 362 patients (41.1%), of which 94 out of 130 (72.3%) and 268 out of 744 (36.0%) belonged to the severe and non-severe COVID- 19 categories, respectively. The odds ratios (95% confidence interval) for male patients, patients with a higher body mass index, patients with severe COVID-19 status, and patients with lower platelet counts were 1.500 (1.029 to 2.184, p=0.035), 1.097 (1.012 to 1.189, p=0.024), 2.377 (1.458 to 3.875, p=0.001), and 0.995 (0.993 to 0.998, p>0.001), respectively, indicating an independent association of these variables with elevated aminotransferase levels. Lopinavir/ ritonavir and antibiotic use increased the odds ratio of abnormal aminotransferase levels after admission (1.832 and 2.646, respectively, both p<0.05). The median time to release from quarantine was longer (22 days vs 26 days, p=0.001) and the mortality rate was higher (13.0% vs 2.9%, p<0.001) in patients with abnormal aminotransferase levels. Conclusions: Abnormal aminotransferase levels are common in COVID-19 patients and are associated with poor clinical outcomes. Multivariate analysis of patients with normal aminotransferase levels on admission showed that the use of lopinavir/ritonavir and antibiotics was associated with abnormal aminotransferase levels; thus, careful monitoring is needed.
참고문헌 (36)
- Jang Jong Geol, "Prognostic Accuracy of the SIRS, qSOFA, and NEWS for Early Detection of Clinical Deterioration in SARS-CoV-2 Infected Patients", Journal of Korean Medical Science, 35(25), pp.1~10 (2020), 대한의학회[DOI]
- Tian S, "Characteristics of COVID-19 infection in Beijing", J Infect, 80, pp.401~406 (2020)
- Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
- Wang D, "Clinical characteristics of 138hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
- Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- Wang Y, "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19", J Hepatol, 73, pp.807~816 (2020)
- "Patient treatment & management" (2020)[URL]
- Shim JJ, "Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B : a large national cohort study", Liver Int, 38, pp.1751~1759 (2018)
- "Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020" (2020)[URL]
- Fan Z, "Clinical features of COVID19-related liver functional abnormality", Clin Gastroenterol Hepatol, 18, pp.1561~1566 (2020)
- Xie H, "Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury : a retrospective study", Liver Int, 40, pp.1321~1326 (2020)
- Zhang Y, "Liver impairment in COVID-19 patients : a retrospective analysis of 115 cases from a single centre in Wuhan city, China", Liver Int, 40, pp.2095~2103 (2020)
- (2020)[URL]
- Hoffmann M, "SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
- Capelli A, "Lung alkaline phosphatase as a marker of fibrosis in chronic interstitial disorders", Am J Respir Crit Care Med, 155, pp.249~253 (1997)
- Guan GW, "Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia", Zhonghua Gan Zang Bing Za Zhi, 28, pp.100~106 (2020)
- Kovalic AJ, "Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes : a systematic review and meta-analysis", Hepatol Int, 14, pp.612~620 (2020)
- Hashemi N, "Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19 : a multicentre United States experience", Liver Int, 40, pp.2515~2521 (2020)
- Kim D, "Predictors of outcomes of COVID-19 in patients with chronic liver disease : US multicenter study", Clin Gastroenterol Hepatol, 19, pp.1469~1479 (2021)
- Yu Rim Lee, "Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea", Clinical and Molecular Hepatology, 26(4), pp.562~576 (2020), 대한간학회
- Qi X, "Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis : a multicentre cohort study", Gut, 70, pp.433~436 (2021)
- Bloom PP, "Liver biochemistries in hospitalized patients with COVID-19", Hepatology, 73, pp.890~900 (2021)
- Singh S, "Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States : a multicenter research network study", Gastroenterology, 159, pp.768~771 (2020)
- Cai Q, "COVID-19 : abnormal liver function tests", J Hepatol, 73, pp.566~574 (2020)
- Cai Q, "Obesity and COVID-19 severity in a designated hospital in Shenzhen, China", Diabetes Care, 43, pp.1392~1398 (2020)
- Docherty AB, "Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study", BMJ, 369, pp.m1985~ (2020)
- Lippi G, "Thrombocytopenia is associated with severe coronavirus disease 2019(COVID-19)infections : a meta-analysis", Clin Chim Acta, 506, pp.145~148 (2020)
- Liu J, "Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients", EBioMedicine, 55, pp.102763~ (2020)
- Cheung A, "Hepatobiliary complications in critically ill patients", Clin Liver Dis, 23, pp.221~232 (2019)
- Goha A, "COVID-19 and the heart : an update for clinicians", Clin Cardiol, 43, pp.1216~1222 (2020)
- Biot C, "Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities", J Med Chem, 49, pp.2845~2849 (2006)
- Devaux CA, "New insights on the antiviral effects of chloroquine against coronavirus:what to expect for COVID-19?", Int J Antimicrob Agents, 55, pp.105938~ (2020)
- Fantini J, "Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARSCoV-2 infection", Int J Antimicrob Agents, 55, pp.105960~ (2020)
- Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19", N Engl J Med, 382, pp.1787~1799 (2020)
- Osborne V, "Lopinavir-ritonavir in the treatment of COVID-19 : a dynamic systematic benefitrisk assessment", Drug Saf, 43, pp.809~821 (2020)